Key result
C reactive protein lacks evidence to support its use for risk stratification or identifying patients with acute coronary syndromes who might benefit from specific treatments.
Why the study?
Does C reactive protein measurement for risk stratification improve treatment selection in patients with acute coronary syndromes?
Does C reactive protein measurement for risk stratification improve treatment selection in patients with acute coronary syndromes?
Current evidence does not support the use of C reactive protein for risk stratification to guide treatment strategies in acute coronary syndromes.
Although C reactive protein is intimately involved with the pathogenic mechanisms that drive acute coronary syndromes, there is no evidence that it is helpful for identifying patient groups who might benefit from particular treatment strategies
No takes yet. Share an insight, caveat, or question.
Simon Kennon (2003) studied this question. C reactive protein lacks evidence to support its use for risk stratification or identifying patients with acute coronary syndromes who might benefit from specific treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: